Speaker 1: Welcome to today's show. I'm Kate Woda, director of the
Speaker 1: Immunooncology three sixty Summit, or most commonly known as IO
Speaker 1: three sixty. The IO three sixty Summit will take place
Speaker 1: February tenth through twelfth in Boston, Massachusetts, and I'm excited
Speaker 1: to give you a sneak peek into what's ahead and
Speaker 1: what we'll be diving into this year and why this
Speaker 1: meeting is so incredibly important in the oncology space. We
Speaker 1: have a lot to cover this year. The science is
Speaker 1: moving fast, the global landscape is evolving, and a great
Speaker 1: deal of innovation is coming out of China right now.
Speaker 1: All of this is shaping the direction of amminooncology and
Speaker 1: IO three sixty is where we come together to unpack
Speaker 1: it all. So what role does IO three sixty play
Speaker 1: in bringing the key stakeholders together. IO three sixty was
Speaker 1: really designed to be the forum that unites every part
Speaker 1: of the cancer immunotherapy ecosystem, from academia and biotech to
Speaker 1: pharma investors and regulators, to share insights, address challenges, and
Speaker 1: accelerate the next generation of immunooncology treatments. It's about collaboration,
Speaker 1: connecting the science with the business to drive meaningful impact
Speaker 1: across cancer types and to make the next wave of
Speaker 1: immunooncology a reality. The summit spans three days and it's
Speaker 1: built on several key pillars pre clinical and discovery, translational,
Speaker 1: clinical development, and business aspects. We also dig into the
Speaker 1: spaces in between biomarkers, ADCs, imaging, cell therapy, autoimmune disease
Speaker 1: combination strategies, and deal making, to name a few. It's
Speaker 1: a packed agenda offering a balance look at both the
Speaker 1: science and the strategy driving the field forward. This year,
Speaker 1: we're especially excited about sessions on novel biologics including cytokines
Speaker 1: by specifics and ADCs, as well as in vivo carti
Speaker 1: and the growing role of AI in advancing amminotherapy. The
Speaker 1: program is intentionally moving beyond PD one I inhibitors and
Speaker 1: beyond just T cell focus, because that's what it takes
Speaker 1: to move the field forward and improve outcomes for people
Speaker 1: living with cancer. And we've built in plenty of flexibility
Speaker 1: so attendees can tailor their experience to focus on what
Speaker 1: matters most to them. Now, let's talk about our incredible
Speaker 1: lineup of keynote speakers. Each of whom is helping define
Speaker 1: the next era of immunooncology. We're delighted to have doctor
Speaker 1: Jed Wallchok of Wheal Cornell Medicine on Checkpoints and Beyond
Speaker 1: the next era of IO. Doctor Miriam Morod of Mount
Speaker 1: Sinai School of Medicine on targeting mylloid cells, Doctor Andrea
Speaker 1: Cursik of Memorial Sloan Kettering Cancer Center on dostor Lamab's
Speaker 1: next chapter, Doctor Ira Mellman of Parker Institute for Cancer
Speaker 1: Ammunotherapy on redefining cancer amunotherapy, and doctor Andrew Baum a
Speaker 1: Pfizer on strategic innovations and industry trends. All of these
Speaker 1: experts share one and thread. They're bringing insights that connect
Speaker 1: the science, the business and the future challenges shaping the
Speaker 1: growth of IO. And of course we'll once again host
Speaker 1: the annual IO three sixty Debate, one of the most
Speaker 1: anticipated sessions every year. It's an entertaining and thought provoking
Speaker 1: way to explore serious topics in oncology, full of insight, honesty,
Speaker 1: and yes, a little humor. It always gets people thinking differently.
Speaker 1: Beyond the sessions, IO three sixty is also about connection.
Speaker 1: You'll find networking breaks, luncheons, event receptions, and a dedicating
Speaker 1: partnering tool that helps facilitate one on one meetings a
Speaker 1: great way to discuss collaborations and partnerships. Our exhibit hall
Speaker 1: is curated specifically for the immunooncology, cell and gene therapy communities.
Speaker 1: It's not overwhelming like a massive trade show. It's the
Speaker 1: perfect balance of learning, connection and exploring. And don't miss
Speaker 1: the poster sessions, which are always a highlight. They create
Speaker 1: another layer of learning and engagement for attendees. For more
Speaker 1: information on the program, full agenda, and ways to participate,
Speaker 1: visit iothree sixty summit dot com. Once again, the IO
Speaker 1: three sixty Summit takes place February ten through twelfth in Boston, Massachusetts.
Speaker 1: We hope to see you there. Thanks for tuning in
Speaker 1: and stay tuned for more updates as we get closer
Speaker 1: to the event.